Invictus MD Announces Conditional Approval to List on the TSX Venture Exchange

Posted on Categories: Investor Relations

VANCOUVER, BC, March 27, 2017 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (CSE: IMH; OTC: IVITF; FRA: 8IS) Invictus MD is pleased to announce it has received conditional approval to list its common shares for trading on the TSX Venture Exchange.

Read more “Invictus MD Announces Conditional Approval to List on the TSX Venture Exchange”

Invictus MD’s AB Laboratories Inc. Provides Cultivation Update under ACMPR

Posted on Categories: Investor Relations

VANCOUVER, BC, March 23, 2017 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (CSE: IMH; OTC: IVITF; FRA: 8IS) Invictus MD announces that AB Laboratories Inc. (“AB Labs”) has successfully completed several test crops in its licensed production facility under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) located in Hamilton, Ontario.

Read more “Invictus MD’s AB Laboratories Inc. Provides Cultivation Update under ACMPR”

Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Posted on Categories: Investor Relations

VANCOUVER, BC, March 14, 2017 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (CSE: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that it has completed its final commitment with a cash transaction of CAD$2,000,000 to acquire 33.33% of AB Laboratories Inc. (“AB Labs”), a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”).

AB Labs is licensed for cultivation under the ACMPR and maintains a 16,000 square foot facility located in Hamilton, Ontario. Invictus MD has the right of first refusal to arrange any initial public offering, reverse take-over or other going public transaction of AB Labs.

Read more “Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.”